AIC-292 is a reverse transcriptase inhibitor potentially for the treatment of HIV infection. AIC292 inhibited wild-type HIV-1 laboratory strains at low nanomolar concentrations, was well tolerated in different cell lines, and showed excellent selectivity in a lead profiling screen. In addition, activity of AIC292 could be demonstrated against a broad panel of wild-type HIV-1 group M and group O clinical isolates. AIC292 also retained activity against viruses harboring NNRTI resistance-associated mutations (RAMs), including the most prevalent variants, K103N, Y181C, and G190A. References: Wildum S, Paulsen D, Thede K, Ruebsamen-Schaeff H, Zimmermann H. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. doi: 10.1128/AAC.01377-13. PubMed PMID: 23959304; PubMed Central PMCID: PMC3811302.

纯度：≥98%

CAS：1187917-12-9